- PA5-28221 - Invitrogen Antibodies ZEB1 antibody

Submitted references Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.

Al-Marsoummi S, Vomhof-DeKrey E, Basson MD
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2019;53(6):999-1014

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y
Cell death and differentiation 2019 May;26(5):943-957

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry-Immunofluorescence analysis of ZEB1 was performed in HeLa cells fixed in 4% paraformaldehyde at RT for 15 min. Green: ZEB1 Polyclonal Antibody (Product # PA5-28221) diluted at 1:500. Red: Phalloidin, a cytoskeleton marker. Scale bar = 10 µm.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Cross-linked ChIP was performed with HeLa chromatin extract and 5 µg of either control rabbit IgG or ZEB1 Polyclonal Antibody (Product # PA5-28221). The precipitated DNA was detected by PCR with primer set targeting to LAMC2 promotor.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: ZEB1 antibody immunoprecipitates ZEB1 protein in IP experiments. IP Sample: 293T whole cell lysate/extract A. 40 µg 293T whole cell lysate/extract B. Control with 2 µg of preimmune rabbit IgG C. Immunoprecipitation of ZEB1 protein by 2 µg of ZEB1 antibody (Product # PA5-28221) 7.5% SDS-PAGE The immunoprecipitated ZEB1 protein was detected by ZEB1 antibody (Product # PA5-28221) diluted at 1:1,000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 ZEB1 regulates the expression of tissue plasminogen activator (tPA), which acts as a paracrine regulator of TGFbeta-induced fibroblast activation. a Increased expression of PLAT (tPA) in IPF epithelial cells is shown by an online LGEA web portal ( https://research.cchmc.org/pbge/lunggens/mainportal.html ). b Quantitative secretome analysis identifies an increased level of tPA in the conditioned media (CM) from 4-OHT-treated ATII ER:KRASV12 cells and a representative tPA Western blot of CM from control or 4-OHT-treated ATII ER:KRASV12 cells. Data are individual values with mean and s.d. n = 3 samples per group. Values were normalised to total fmol of each sample multiplied by 10,000. c Fold change in mRNA levels of ZEB1 and PLAT (tPA) in ATII ER:KRASV12 cells with indicated treatments. beta-actin-normalised mRNA levels in control cells were used to set the baseline value at unity. Data are mean +- s.d. n = 3 samples per group. *** P < 0.001. d ChIP assays of ZEB1's ability to bind the PLAT (tPA) promoter in ATII ER:KRASV12 cells with indicated treatments. The amplified PLAT (tPA) promoter region (-547 to -345) contains a ZEB1 binding site at -419. Values represent relative binding in relation to input (2%), normalised against control (1.0). Data are mean +- s.d. n = 4 samples per group. *** P < 0.001. e PLAT promoter reporter assays in ATII ER:KRASV12 cells with indicated treatments. Values represent relative fold of firefly luciferase in relation to Renilla luciferase,

PA5-28221

Antibody data